PLX
Price
$1.91
Change
+$0.10 (+5.52%)
Updated
Sep 15 closing price
Capitalization
152.29M
62 days until earnings call
PRME
Price
$4.01
Change
-$0.06 (-1.47%)
Updated
Sep 15 closing price
Capitalization
714.88M
45 days until earnings call
Interact to see
Advertisement

PLX vs PRME

Header iconPLX vs PRME Comparison
Open Charts PLX vs PRMEBanner chart's image
Protalix BioTherapeutics
Price$1.91
Change+$0.10 (+5.52%)
Volume$1.35M
Capitalization152.29M
Prime Medicine
Price$4.01
Change-$0.06 (-1.47%)
Volume$2.36M
Capitalization714.88M
PLX vs PRME Comparison Chart in %
Loading...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PLX vs. PRME commentary
Sep 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLX is a StrongBuy and PRME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 16, 2025
Stock price -- (PLX: $1.91 vs. PRME: $4.01)
Brand notoriety: PLX and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PLX: 216% vs. PRME: 62%
Market capitalization -- PLX: $152.29M vs. PRME: $714.88M
PLX [@Biotechnology] is valued at $152.29M. PRME’s [@Biotechnology] market capitalization is $714.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLX’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • PLX’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PLX is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PLX’s TA Score shows that 6 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • PLX’s TA Score: 6 bullish, 4 bearish.
  • PRME’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, PLX is a better buy in the short-term than PRME.

Price Growth

PLX (@Biotechnology) experienced а +20.89% price change this week, while PRME (@Biotechnology) price change was +3.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.37%. For the same industry, the average monthly price growth was +6.67%, and the average quarterly price growth was +33.69%.

Reported Earning Dates

PLX is expected to report earnings on Nov 17, 2025.

PRME is expected to report earnings on Oct 31, 2025.

Industries' Descriptions

@Biotechnology (+2.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($715M) has a higher market cap than PLX($152M). PRME YTD gains are higher at: 37.329 vs. PLX (1.596). PLX has higher annual earnings (EBITDA): 10.4M vs. PRME (-197.38M). PRME has more cash in the bank: 102M vs. PLX (33.4M). PLX has less debt than PRME: PLX (5.35M) vs PRME (120M). PLX has higher revenues than PRME: PLX (61.9M) vs PRME (4.96M).
PLXPRMEPLX / PRME
Capitalization152M715M21%
EBITDA10.4M-197.38M-5%
Gain YTD1.59637.3294%
P/E Ratio21.22N/A-
Revenue61.9M4.96M1,248%
Total Cash33.4M102M33%
Total Debt5.35M120M4%
FUNDAMENTALS RATINGS
PLX vs PRME: Fundamental Ratings
PLX
PRME
OUTLOOK RATING
1..100
186
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5299
PRICE GROWTH RATING
1..100
4436
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
4438

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PLX's Valuation (57) in the Servicestothe Health Industry industry is in the same range as PRME (67) in the null industry. This means that PLX’s stock grew similarly to PRME’s over the last 12 months.

PLX's Profit vs Risk Rating (100) in the Servicestothe Health Industry industry is in the same range as PRME (100) in the null industry. This means that PLX’s stock grew similarly to PRME’s over the last 12 months.

PLX's SMR Rating (52) in the Servicestothe Health Industry industry is somewhat better than the same rating for PRME (99) in the null industry. This means that PLX’s stock grew somewhat faster than PRME’s over the last 12 months.

PRME's Price Growth Rating (36) in the null industry is in the same range as PLX (44) in the Servicestothe Health Industry industry. This means that PRME’s stock grew similarly to PLX’s over the last 12 months.

PLX's P/E Growth Rating (97) in the Servicestothe Health Industry industry is in the same range as PRME (100) in the null industry. This means that PLX’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PLXPRME
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LEAIX15.04N/A
N/A
Lazard Emerging Markets Eq Advtg Instl
MEFOX70.55N/A
N/A
Meehan Focus
GEGTX86.20N/A
N/A
Columbia Cornerstone Growth Inst
CNZLX12.49N/A
N/A
Commonwealth Australia/New Zealand
CLEYX22.91N/A
N/A
Columbia Cornerstone Equity Inst 3

PLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PLX has been loosely correlated with IOVA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PLX jumps, then IOVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
+5.52%
IOVA - PLX
46%
Loosely correlated
N/A
STOK - PLX
31%
Poorly correlated
-0.26%
ZNTL - PLX
31%
Poorly correlated
-2.68%
CPRX - PLX
31%
Poorly correlated
-1.05%
SNDX - PLX
31%
Poorly correlated
+1.86%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-1.47%
CRSP - PRME
57%
Loosely correlated
+2.81%
BEAM - PRME
53%
Loosely correlated
+3.30%
RXRX - PRME
53%
Loosely correlated
-1.24%
CRBU - PRME
47%
Loosely correlated
+1.67%
EDIT - PRME
46%
Loosely correlated
-0.74%
More